Karyopharm Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.01.25	Karyopharm Therapeutics Appoints Lori Macomber As CFO (RTTNews)
08.05.24	Karyopharm Therapeutics Inc. Q1 Loss increases, but beats estimates (RTTNews)
29.02.24	Karyopharm Therapeutics Inc. Q4 Loss misses estimates (RTTNews)
06.11.23	Karyopharm : Data In Selinexor-Treated Patients With Endometrial Cancer Shows Improvements In PFS (RTTNews)
30.10.23	Karyopharm Enters Clinical Trial Collaboration, Supply Agreement With Bristol-Myers Squibb (RTTNews)
02.08.23	Karyopharm Therapeutics Inc. Q2 Loss decreases, beats estimates (RTTNews)
21.02.23	Karyopharm Announces Full Marketing Authorization For NEXPOVIO In The UK (RTTNews)
12.12.22	Karyopharm Announces Updated Phase 1 Data Of Selinexor Combination In Treatment-Naïve Myelofibrosis (RTTNews)
01.11.22	Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis (PR Newswire)
21.07.22	Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Pri... (PR Newswire)
20.05.22	Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma (PR Newswire)
20.04.22	Pre-market Movers: NFLX, RMNI, LYRA, BW, NEWP… (RTTNews)
02.03.22	Pre-market Movers: JWN, KPTI, BORR, SOFI, HOOK… (RTTNews)
08.02.22	Karyopharm : Phase 3 Study Of Selinexor Meets Primary Endpoint In Recurrent Endometrial Cancer (RTTNews)
24.01.22	Karyopharm Receives FDA's Orphan Drug Designation For Eltanexor - Quick Facts (RTTNews)
21.12.21	Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories (PR Newswire)
21.12.21	Menarini Group To Commercialize Karyopharm's NEXPOVIO In Europe - Quick Facts (RTTNews)
17.12.21	Antengene Receives Approval In China For XPOVIO For Treatment Of Refractory Multiple Myeloma (RTTNews)
05.08.21	Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results (PR Newswire)
03.08.21	Karyopharm Announces Upcoming Virtual Investor Conference Participation (PR Newswire)
29.07.21	Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021 (PR Newswire)
28.07.21	Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis (PR Newswire)
01.07.21	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
24.06.21	Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million (PR Newswire)
09.06.21	Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress (PR Newswire)
09.06.21	Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS (PR Newswire)
09.06.21	Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS (PR Newswire)
08.06.21	Karyopharm Announces Key Changes to Its Commercial Leadership Team (PR Newswire)
05.02.21	JNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovio's Footprint, OTLK On Track (RTTNews)
21.12.20	FDA Approves Karyopharm's Xpovio To Treat Multiple Myeloma After At Least One Prior Therapy (RTTNews)
03.11.20	AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial (RTTNews)
23.06.20	MYOV To Report SPIRIT 1 Data, EVLO Joins COVID-19 Drug Race, NVTA Loosens Purse Strings (RTTNews)
01.06.20	Karyopharm In Pursuit Of Wider Use Of Xpovio (RTTNews)
26.05.20	Biotech Stocks Facing FDA Decision In June 2020 (RTTNews)
08.04.20	KPTI To Test XPOVIO In COVID-19, PTCT Will Have To Wait, SAGE Slashes Workforce (RTTNews)
03.03.20	RCEL On The Move, FTSV Acquired, NCNA On Watch, FDA Nod For SNY, COVID-19 Update (RTTNews)
20.02.20	FDA Delays Decision On HRTX Drug, KPTI On Watch, ADMP To Resubmit NDA In Q2 (RTTNews)
17.09.19	XLRN Pulls The Plug On FSHD Study, KPTI Well Funded, ACRS Up On Wart Trial Data (RTTNews)
05.07.19	Karyopharm On The Move… (RTTNews)
03.07.19	6 Top Gainers In Healthcare Sector (AMRN, DOVA, IMUX...) (RTTNews)
26.06.19	Biotech Stocks Facing FDA Decision In July 2019 (RTTNews)
15.03.19	ATOS Skyrockets, BPMX Gets "Going Concern" Warning, Respite For KPTI (RTTNews)
24.02.19	ACHV Soared As Much As 145%. What Awaits SRPT, HTBX, KPTI This Week? (RTTNews)
09.01.19	Japan Approves Amgen/UCB's Osteoporosis Drug - Will U.S. Follow Suit? (RTTNews)
09.06.18	An Ear To The Pharma: 8 Stocks To Watch (CMRX, CRBP, KPTI, VRX…) (RTTNews)
03.05.18	AKAO Slumps On FDA Panel Vote, ESPR Awaits Data In May, STAA Shines (RTTNews)
02.05.18	AKAO On Watch, SCYX To Report Data In July, FDA Panel Nod For SIGA (RTTNews)
01.05.18	INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM (RTTNews)
11.04.18	AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch (RTTNews)
25.01.18	Biogen To Acquire Karyopharm's Investigational Oral SINE Compound KPT-350 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	28.46	2.63 %	K V
Swiss Life Hldg	712.60	1.86 %	K V
Part Grp Hldg	1’245.50	1.26 %	K V
Zurich Insur Gr	545.00	1.15 %	K V
Swiss Re	132.70	1.14 %	K V
Givaudan	3’945.00	-0.53 %	K V
Geberit	511.20	-0.66 %	K V
Alcon	76.38	-0.68 %	K V
Sika	212.90	-1.34 %	K V
CieFinRichemont	134.25	-2.65 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Karyopharm Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten